Page 3 - Cipla Results

Launch delays key risk to outlook for pharma company Cipla stock

The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business

Cipla's net profit jumps 32% to Rs 1,055.9 crore in third quarter

Cipla advanced its board meeting to January 22 to approve its results for the quarter and nine months ended December 31, 2023, to avoid confusion following an alleged social media leak

Cipla forges strategic partnership for global cell therapy advancements

The collaborative effort is aimed at developing and commercialising novel Cell therapy products for critical unmet medical needs in the US, Japan, and the EU

Sensex, Nifty take breather after 3-day winning run; pharma, PSBs rally

Closing Bell on November 7, 2023: The broader markets, on the other hand, held steady gains throughout the session, settling 0.53 per cent and 0.38 per cent higher, respectively

Cipla surges 4% on beating Q2 estimates; profit jumps 43%, revenue up 15%

The positive growth was aided by strength in domestic as well as US sales. Its overall Q2 revenue was its highest ever in a quarter, Cipla said.

Cipla Q2 results: Profit surges 43% to Rs 1,131 crore on strong US sales

Cipla beat Bloomberg estimates which had pegged revenues at around Rs 6,490 crore and net income at Rs 984 crore

Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn

Cipla Q2FY24 result preview: On a sequential basis (QoQ), Cipla's net profit is seen declining 1.1 per cent, while revenue may grow 2.2 per cent

Improving US outlook, margin gains keep Street positive on Cipla stock

Lower depreciation led to a 45 per cent increase in adjusted net profit and the same was 25-35 per cent higher than what the street had estimated

Cipla Q1 PAT up 45% YoY to Rs 996 crore on strong India, US business

Cipla said that its key asset Lanreotide (hormonal drug) has improved its market share to 18 per cent. And, its focus continues on limited competition launches

Cipla Q1FY24 result: Net profit at Rs 895.02 crore; revenue up by 12.2%

The company's One-India business grew by 12 per cent YoY. Their US business reported highest-ever revenue of $222 million and 43 per cent YoY growth

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

Cipla Q2 net profit up 12% at Rs 797 crore, revenue rises to Rs 5,829 crore

Drug major Cipla on Friday said its consolidated net profit increased 12 per cent to Rs 797 crore for the second quarter ended September 30. The Mumbai-based drug maker had reported a consolidated net profit of Rs 709 crore in the July-September period of the previous fiscal. Its total revenue from operations rose to Rs 5,829 crore for the September quarter from Rs 5,520 crore in the year-ago period, Cipla said in a regulatory filing. In respect of the transfer of India-based US business undertaking, the board decided not to proceed with the proposed transfer, considering various factors, including the current operating environment, it added. Shares of the company were trading 0.5 per cent up at Rs 1,154.10 apiece on the BSE.

Stocks to Watch: YES Bank, Cipla, Bank of Baroda, Zomato, HDFC, ITC, NTPC

Stocks to Watch today: ITC, UPL, Zomato, Arvind, Bajaj Consumer Care, among others will release their Q1 earnings today.

Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales

Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Sensex snaps 5-day losing run, ends 367 pts up; Nifty holds 17,250

Bargain buying in banking and auto counters amid better-than-expected Q3 results by Axis Bank and Maruti Suzuki pushed the index 367 points higher at 57,858 level at close

Cipla hits record high on strong Q1 result; Morgan Stanley sees 30% upside

Mumbai headquartered pharma firm posted 20% growth in profit before tax for the first quarter of the current financial year to Rs 799 crore, on a 9% YoY growth in revenues to Rs 4,346 crore